Cerebral malaria (CM) is the most severe and life-threatening neurological complication of Plasmodium falciparum infection, defined by unarousable coma (GCS <11 in adults; Blantyre Coma Score <3 in children) in a patient with P. falciparum parasitemia after exclusion of other causes of encephalopathy. [1-2] Mortality ranges from 15–25% even with optimal treatment, and ~10% of survivors have persistent neurological sequelae. [1][3]
1. History
- Travel history is the single most critical HPI element in non-endemic settings — destination, dates, duration, and malaria chemoprophylaxis adherence [4-5]
- Symptom onset: fever, chills, rigors, headache, myalgias, vomiting, diarrhea — typically 1 week to 2 months after exposure for P. falciparum (rarely >60 days) [5]
- Progression: ask about declining consciousness, confusion, seizures, inability to eat/drink, prostration (inability to sit/stand) [2][4]
- Timing of fever: classically paroxysmal every 48 hours, but this pattern is highly variable and often absent [5]
- Important negatives: neck stiffness (meningitis), rash (meningococcemia), focal neurological deficits (stroke/abscess), recent antibiotic use, HIV status
2. Alarm Features
- Unarousable coma (GCS <11 / Blantyre <3) [2]
- Repeated seizures (>2 in 24 hours), especially prolonged or subtle (conjugate eye deviation, nystagmus, salivation) [2-3]
- Abnormal motor posturing (decerebrate/decorticate) — suggests raised ICP [3-4]
- Respiratory distress / Kussmaul breathing — marker of severe metabolic acidosis and powerful independent predictor of death [3][6]
- Shock (SBP <80 mmHg adults / <70 mmHg children with impaired perfusion) [2]
- Hypoglycemia (glucose <40 mg/dL) — can cause or worsen coma [2]
- Hyperparasitemia (>10% in endemic areas; ≥5% in non-immune travelers) [2]
- Blackwater fever (hemoglobinuria) [4]
The following figure from a landmark study of Kenyan children illustrates how the overlap of impaired consciousness, respiratory distress, and severe anemia dramatically increases mortality:
3. Medications
- First-line treatment: IV artesunate — 2.4 mg/kg at 0, 12, and 24 hours, then every 24 hours; use 3.0 mg/kg if body weight <20 kg [4][7]
- Alternatives if artesunate unavailable: IM artemether (3.2 mg/kg loading, then 1.6 mg/kg daily) or IV quinine (20 mg/kg loading over 4 hours, then 10 mg/kg q8h) [4]
- Pre-referral: rectal artesunate in primary care settings where parenteral therapy is unavailable [4]
- Transition to oral ACT (e.g., artemether-lumefantrine) once parasitemia ≤1% and patient tolerates PO, after minimum 24 hours of IV therapy [2][4]
- Contraindicated/harmful adjunctive therapies: Mannitol (increased mortality and prolonged coma), dexamethasone, anti-TNF antibodies — over 32 RCTs of adjunctive therapies have shown no benefit [8]
- Quinidine caution: QRS widening and QTc prolongation — requires cardiac monitoring and cardiology consultation [9]
- Phenobarbitone for seizures should not be given without respiratory support available [4]
4. Diet
- NPO during coma — NG tube for medications and glucose supplementation as needed
- Frequent glucose monitoring is essential; hypoglycemia is common and can be exacerbated by quinine (stimulates insulin secretion) [2]
- Cautious IV fluids — aggressive fluid therapy worsens cerebral edema and pulmonary edema; restrictive fluid management is preferred [4][8]
- Post-recovery: gradual reintroduction of oral intake; address nutritional rehabilitation, as recurrent malaria causes malnutrition [4]
5. Review of Systems
- Neurological: level of consciousness, seizure activity (including subtle signs), focal deficits, visual changes
- Respiratory: dyspnea, tachypnea, deep labored breathing (Kussmaul's — often misinterpreted as cardiac failure) [3]
- GI: vomiting, diarrhea, abdominal pain, jaundice, inability to eat/drink
- Renal: urine output, dark urine (hemoglobinuria/blackwater fever)
- Hematologic: bleeding from gums, nose, venipuncture sites; melena, hematemesis [2]
- Obstetric (if applicable): pregnancy status — pregnant women are at increased risk of hypoglycemia, severe anemia, and placental malaria [4-5]
6. Collateral History and Family History
- Collateral: travel companions' illness, exact itinerary in endemic areas, sleeping conditions (bed nets), chemoprophylaxis compliance, prior malaria episodes
- Immune status: individuals from endemic areas who have been away >6 months may have lost partial immunity [5]
- HIV status: immunosuppressed patients lose acquired malarial immunity and are at increased risk of severe outcomes [5]
- Family history: hemoglobinopathies (sickle cell trait, thalassemia, G6PD deficiency) affect susceptibility and treatment choices (primaquine contraindicated in G6PD deficiency) [7]
7. Risk Factors
- Non-immune travelers to endemic areas (highest risk group in non-endemic settings) [5]
- Children <5 years in endemic areas (before acquired immunity develops) [3][5]
- Pregnant women, especially primigravidas [4]
- HIV-immunosuppressed individuals [5]
- No or incomplete chemoprophylaxis [5]
- Delayed diagnosis and treatment — uncomplicated malaria can progress to severe disease within hours [5]
- High parasitemia (>5% in non-immune; >10% in semi-immune) [2]
- Splenectomized patients
8. Differential Diagnosis
- Bacterial meningitis — neck stiffness, rash; LP is essential to exclude; co-infection occurs in ~27% of children with CM [4][10]
- Viral encephalitis (HSV, arboviruses, Japanese encephalitis) — focal deficits, temporal lobe involvement on imaging [7]
- Bacterial sepsis / septic encephalopathy — positive blood cultures, no parasitemia [7]
- Typhoid encephalopathy — prolonged fever, abdominal symptoms, rose spots [7]
- Hypoglycemic encephalopathy — must be ruled out immediately with bedside glucose [8]
- Metabolic encephalopathy (hepatic, uremic, DKA)
- Viral hemorrhagic fever (Ebola, Lassa) — hemorrhage, epidemiologic exposure [7]
- Dengue with severe features — rash, severe myalgia, hemorrhagic manifestations [7]
- Post-ictal state — prolonged postictal coma (>1 hour) can mimic CM; subclinical seizure activity is common [3]
- Key distinguishing feature: Malarial retinopathy is the best clinical feature to distinguish true CM from non-malarial coma with incidental parasitemia [3][11]
9. Past Medical History
- Prior malaria episodes and species (partial immunity status)
- Previous severe malaria or cerebral malaria
- Splenectomy or functional asplenia
- G6PD deficiency (affects treatment with primaquine/tafenoquine for P. vivax/ovale co-infection)
- Chronic kidney disease, liver disease (affects drug metabolism)
- Sickle cell disease/trait
- Immunosuppressive conditions or medications
10. Physical Exam
- Vitals: fever (often high), tachycardia, tachypnea, hypotension (late/ominous), SpO₂
- Neurological:
- GCS/Blantyre Coma Score — serial assessments [2]
- Pupil size and reactivity
- Abnormal posturing (decerebrate/decorticate) — suggests raised ICP [3]
- Subtle seizure signs: conjugate eye deviation, nystagmus, salivation, hypoventilation [3]
- Meningismus (suggests co-infection or alternative diagnosis)
- Fundoscopy: Malarial retinopathy — retinal whitening, vessel changes, hemorrhages — pathognomonic for CM and the best bedside discriminator from non-malarial coma [3][11]
- Respiratory: Kussmaul breathing (deep, labored) — indicates metabolic acidosis [3]
- Abdominal: hepatosplenomegaly, jaundice
- Skin: pallor (anemia), jaundice, petechiae, bleeding from venipuncture sites
- Capillary refill: ≥3 seconds indicates compensated shock [4]
11. Lab Studies
- Thick and thin blood smears — gold standard for diagnosis and speciation; quantify parasitemia (% infected RBCs); at least 3 smears 8–12 hours apart before excluding diagnosis [11]
- Rapid diagnostic test (RDT) — HRP2-based (for P. falciparum) or pLDH-based; useful when microscopy unavailable [11]
- CBC: anemia (Hgb <7 g/dL = severe), thrombocytopenia (common and supportive of diagnosis) [4]
- Metabolic panel: glucose (<40 mg/dL = severe), creatinine (>3 mg/dL = severe AKI), BUN, electrolytes [2]
- Lactate / ABG: lactate ≥5 mmol/L or bicarbonate <15 mmol/L = severe acidosis [2]
- LFTs / bilirubin: bilirubin >3 mg/dL with parasitemia >100,000/μL = severe [2]
- LDH, haptoglobin, reticulocyte count — hemolysis markers; also monitor for post-artesunate delayed hemolysis [2][8]
- Blood cultures — bacterial co-infection (especially Salmonella spp.) occurs in 5–12% of children with severe malaria [4]
- CSF analysis (via LP) — to exclude meningitis; mild pleocytosis and elevated protein may be seen in CM; elevated CSF lactate is associated with increased mortality [11]
- Coagulation studies — DIC screening
- HIV testing — affects prognosis and management [5]
12. Imaging
- CT head — indicated urgently if focal neurological deficits, signs of raised ICP, or to rule out alternative diagnoses before LP
- MRI brain — gold standard for characterizing CM pathology; shows diffuse cerebral edema/brain swelling (the central radiological finding, strongly associated with mortality in children), restricted diffusion, and features resembling posterior reversible encephalopathy syndrome (PRES) in a subset [4][10][12]
- Chest X-ray — to evaluate for pulmonary edema/ARDS (can develop during or after treatment) [2]
- Imaging is not required to initiate treatment — do not delay IV artesunate for imaging
13. Special Tests
- Malarial retinopathy assessment (dilated fundoscopy by trained examiner) — the single best clinical feature distinguishing true CM from non-malarial coma with incidental parasitemia [3][11]
- Blantyre Coma Score (children): Motor (0–2), Verbal (0–2), Eye (0–1); score ≤2 = coma [12]
- Glasgow Coma Scale (adults): <11 defines cerebral malaria per WHO [2]
- EEG — identifies subclinical seizures and non-convulsive status epilepticus (common in CM); EEG features can distinguish malarial from non-malarial coma (AUROC 0.85–0.90) [10][13]
- Transcranial Doppler — can assess cerebral blood flow and raised ICP non-invasively [14]
- Optic nerve sheath diameter (ONSD) — non-invasive ICP estimation [1]
- Lumbar puncture — safe in CM (demonstrated in 866 patients); essential to exclude meningitis; measure opening pressure [2][11]
14. ECG
- Indicated if using quinidine or quinine — monitor for QRS widening and QTc prolongation [9]
- Continuous cardiac monitoring required during quinidine infusion; cardiology consultation recommended [9]
- Severe complications may warrant temporary discontinuation or slowing of infusion [9]
- Electrolyte abnormalities (hypokalemia, hypocalcemia) in severe malaria can contribute to arrhythmias
- Artesunate does not have significant cardiac toxicity
15. Assessment
Cerebral malaria is a medical emergency with 15–25% mortality even with optimal treatment. [1][15] Key pathophysiology involves parasitized erythrocyte sequestration in cerebral microvasculature, immune hyperactivation, blood-brain barrier disruption, and cerebral edema. [1][4]
Three clinical phenotypes are recognized: [3]
- Coma with marked physiological derangement (severe anemia, acidosis, shock)
- Coma with protracted/multiple seizures (postictal or subclinical seizure activity)
- Pure neurological syndrome with coma and abnormal posturing ± raised ICP
Complications to anticipate: cerebral edema/herniation, status epilepticus, severe metabolic acidosis, AKI, ARDS (often post-treatment), DIC, hypoglycemia, severe anemia, and bacterial co-infection. [2][4]
16. Treatment Plan
Immediate stabilization
- ABCs — intubate for airway protection in comatose patients where available [4]
- IV artesunate 2.4 mg/kg at 0, 12, and 24 hours, then daily (3.0 mg/kg if <20 kg); minimum 3 doses before considering oral transition [4][7]
- Check and correct hypoglycemia immediately (IV dextrose); monitor glucose frequently [2]
- Restrictive IV fluids — avoid aggressive hydration (worsens cerebral and pulmonary edema) [4][8]
Seizure management
- Treat acute seizures with benzodiazepines; avoid phenobarbitone without ventilatory support [4]
- Monitor for subclinical seizures with EEG if available [13]
Supportive care
- Blood transfusion for severe anemia (Hgb <5 g/dL in endemic areas; <7 g/dL in low-transmission settings) [4]
- Empirical antibiotics — strongly consider in all patients with febrile coma given high rate of bacterial co-infection (27% in one cohort), especially Salmonella spp. and S. pneumoniae [4][10]
- Acetaminophen — safe and may have renal protective effects [2][8]
- Renal replacement therapy for severe AKI with acidosis, hyperkalemia, or fluid overload [4]
- Monitor parasitemia every 12 hours until <1% [7]
Transition to oral therapy
Therapies with NO proven benefit: mannitol (harmful — increased mortality), dexamethasone, exchange transfusion, anti-TNF agents, inhaled nitric oxide [8]
17. Disposition
- All patients with cerebral malaria require ICU admission — continuous monitoring of neurological status, hemodynamics, glucose, and respiratory function [1-2]
- Intubation and mechanical ventilation for airway protection in comatose patients [4]
- Specialist consultation: infectious disease, critical care, neurology; cardiology if quinidine is used [9]
- CDC Malaria Hotline (in the US): 770-488-7788 (M–F) or 770-488-7100 (after hours) — for diagnostic and treatment guidance [8]
- Do not discharge until: consciousness fully recovered, parasitemia cleared or <1% on oral therapy, hemodynamically stable, tolerating oral medications, no ongoing organ dysfunction
- Most children with CM regain consciousness within 48 hours [3]
18. Follow Up / Return Precautions
- Post-artesunate delayed hemolysis: monitor hemoglobin, LDH, and haptoglobin weekly for 4 weeks after IV artesunate — occurs in ~5% of patients, typically 7–21 days post-treatment, especially with high initial parasitemia [2][4][8]
- Neurocognitive assessment: screen for cognitive impairment, behavioral changes, motor deficits, epilepsy, and visual deficits — ~10% of survivors have persistent neurological sequelae [3-4][14]
- Repeat blood smears to confirm parasite clearance
- Return precautions: immediate return for recurrent fever, headache, confusion, seizures, dark urine, jaundice, decreased urine output, or inability to tolerate oral medications
- Malaria chemoprophylaxis counseling for future travel [5]
- Post-discharge malaria chemoprophylaxis in endemic settings reduces mortality from residual severe anemia [4]
- Expected recovery: most patients regain consciousness within 48 hours; full neurological recovery is common but long-term cognitive and behavioral sequelae should be monitored over months [3][14]
References
1. Management and Monitoring Strategies for Severe Cerebral Malaria: A Guide for the Intensivist. — Vathi S, Corriero A, Rodríguez EE, et al. Annals of Intensive Care. 2025.
2. Malaria. — Daily JP, Parikh S. The New England Journal of Medicine. 2025.
3. Malaria in Children. — Crawley J, Chu C, Mtove G, Nosten F. Lancet. 2010.
4. Malaria. — Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Lancet. 2023.
5. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. — Constance Benson, John Brooks, Shireesha Dhanireddy, et al Infectious Diseases Society of America; Office of AIDS Research Advisory Council (2025). 2025.
6. Indicators of Life-Threatening Malaria in African Children. — Marsh K, Forster D, Waruiru C, et al. The New England Journal of Medicine. 1995.
7. Malaria: Prevention, Diagnosis, and Treatment. — Shahbodaghi SD, Rathjen NA. American Family Physician. 2022.
8. Diagnosis, Treatment, and Prevention of Malaria in the US: A Review. — Daily JP, Minuti A, Khan N. The Journal of the American Medical Association. 2022.
9. Guidelines for the Prevention and Treatment of Opportunistic Infections in Children With and Exposed to HIV. — Bill G. Kapogiannis, Franklin Yates, Wei Li, et al Office of AIDS Research Advisory Council (2025). 2025.
10. Aetiologies, Neuroradiological Features, and Risk Factors for Mortality and Long-Term Neurosequelae of Febrile Coma in Malawian Children: A Prospective Cohort Study. — Ray STJ, Fuller CE, Ahmadu A, et al. The Lancet. Global Health. 2025.
11. Pathogenesis, Clinical Features, and Neurological Outcome of Cerebral Malaria. — Idro R, Jenkins NE, Newton CR. The Lancet. Neurology. 2005.
12. Brain Swelling and Death in Children with Cerebral Malaria. — Seydel KB, Kampondeni SD, Valim C, et al. The New England Journal of Medicine. 2015.
13. Electroencephalogram Features Distinguish Cases of Cerebral Malaria Among Malawian Children With Fever and Coma. — Andrews A, Harrar DB, Zelleke T, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025.
14. Cerebral Malaria. — Postels DG, Katangwe-Chirwa T. Seminars in Pediatric Neurology. 2025.
15. Pathogenetic Mechanisms and Treatment Targets in Cerebral Malaria. — Hadjilaou A, Brandi J, Riehn M, Friese MA, Jacobs T. Nature Reviews. Neurology. 2023.